Computed tomography after lymphangiography in the diagnosis of intestinal lymphangiectasia with protein-losing enteropathy in Noonan's syndrome.

Department of Radiology, Universität Würzburg, Germany.
European Radiology (Impact Factor: 4.34). 02/2000; 10(10):1591-3. DOI: 10.1007/s003300000384
Source: PubMed

ABSTRACT Noonan's syndrome is a rare congenital disorder that may be associated with abnormalities in the lymphatic drainage. In this case of a 21-year-old man CT after bipedal lymphangiography confirmed the diagnosis of intestinal lymphangiectasy causing protein-losing enteropathy in Noonan's syndrome by showing contrast-enhanced abnormal lymphatic vessels in the mesentery and the intestinal wall. Because of the benefit of diet in case of intestinal involvement, we recommend a thorough documentation of the lymphatic drainage with lymphangiography followed by CT, if clinical signs of lymphatic dysplasia, such as pleural effusions, lymphedema, or hypoproteinemia are present.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Noonan syndrome is characterized by facial dysmorphology, congenital heart disease and growth failure. Although it is also accompanied by deranged lymph-vessel formation, protein-losing enteropathy (PLE) with Noonan syndrome is rarely reported. We report clinical information about a boy with Noonan syndrome and late-onset lymphedema and PLE after standing for long periods of time during athletic practice sessions. The boy recovered from lymphedema and PLE after administration of 2.5 g of albumin followed by resting and raising his legs. They did not recur after he began walking again. Standing for long periods of time congested the lymph stream at the abdominal lymph vessel, whose formation is frequently disturbed in Noonan syndrome, and the increased pressure caused lymphedema and PLE. PLE is one of the clinical manifestations of Noonan syndrome.
    Clinical Pediatric Endocrinology 07/2009; 18(3):87-93.
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung In unserer Klinik stellte sich ein 43-jhriger Patient mit chronischer Diarrh vor. Die Untersuchung der &#1021-Antitrypsinclearance im Stuhl belegte eine exsudative Enteropathie. Daneben imponierten eine ausgeprgte Lymphozytopenie sowie in histopathologischen Untersuchungen von Biopsiematerial aus Dnn- und Dickdarm eine diffuse Lymphangiektasie. Wir stellten die Diagnose einer primren intestinalen Lymphangiektasie, nachdem differenzialdiagnostisch sekundre Formen ausgeschlossen worden waren. Die zustzlich bestehenden morphologischen und anamnestischen Aufflligkeiten legen den hochgradigen Verdacht auf das Vorliegen eines Noonan-Syndroms nahe. Zu dessen Manifestationen zhlen Vernderungen des Lymphgefsystems im Sinne einer primren Lymphangiektasie. Diese Vernderungen sind hufig pulmonal lokalisiert, eine intestinale Lymphangiektasie beim Noonan-Syndrom ist bisher nur in wenigen Einzelfllen beschrieben. Unter einer eiweireichen Dit, deren reduzierter Fettanteil mit mittelkettigen Fettsuren angereichert ist, und Injektionen von 2-mal tglich 200 g Octreotid s.c. besserte sich die Symptomatik deutlich. Abstract A 43-year old patient came to our clinic with chronic diarrhea. Determination of the faecal &#1021-antitrypsin-clearance led to the diagnosis of exsudative enteropathy. Blood counts showed pronounced lymphocytopenia. Histopathological findings from intestinal and colorectal biopsies showed diffuse lymphangiectasis. Following exclusion of secondary types, our diagnosis was primary intestinal lymphangiectasis. Additional distinctive morphological and anamnestic features strongly suggested presence of Noonan's syndrome. Characteristic manifestations of Noonan's syndrome include changes in the lymphatic vessels in accordance with primary lymphangiectasis. Frequently, these changes are localized in the lungs. To date, only rare cases of intestinal lymphangiectasia in Noonan's syndrome have been reported. Treatment consisted of a protein-rich diet, with reduced fat content enriched by middle-chain fatty acids, as well as twice-daily injections of 200 g octreotide. With this therapy, the symptoms improved.
    Der Internist 04/2003; 44(5):626-630. · 0.33 Impact Factor